SymbolANRO
NameALTO NEUROSCIENCE, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, California, 94041, United States
Telephone+1 650 200-0412
Fax
Email
Websitehttps://www.altoneuroscience.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.

Additional info from NASDAQ:
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.

2026-04-21 12:03

Alto Neuroscience, Inc. - Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Read more
2026-04-21 07:04

New Form EFFECT - Alto Neuroscience, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 9999999995-26-001257 <b>Size:</b> 1 KB

Read more
2026-04-10 17:02

New Form S-3 - Alto Neuroscience, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001104659-26-041959 <b>Size:</b> 784 KB

Read more
2026-04-01 20:55

(90% Positive) ALTO NEUROSCIENCE, INC. (ANRO) Provides Update on medicines for schizophrenia

Read more
2026-04-01 20:30

Alto Neuroscience, Inc. - Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Read more
2026-04-01 20:30

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Read more
2026-03-26 17:11

New Form ARS - Alto Neuroscience, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001104659-26-035202 <b>Size:</b> 2 MB

Read more
2026-03-26 17:08

New Form DEFA14A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001104659-26-035191 <b>Size:</b> 456 KB

Read more
2026-03-26 17:06

New Form DEF 14A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001104659-26-035180 <b>Size:</b> 3 MB

Read more
2026-03-16 11:08

(80% Positive) ALTO NEUROSCIENCE, INC. (ANRO) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment

Read more
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Apollo Armband DEVICE Approved Fatigue COMPLETED NCT04983342
Apollo Wearable DEVICE Approved Stress Disorders, Post-Traumatic RECRUITING NCT05274230
Total products: 2